Clinical trial
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV…
NCT00428922 · Bhuvaneswari Ramaswamy, Other · Completed
Key facts
| NCT number | NCT00428922 |
|---|---|
| Title | Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients |
| Official title | Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients |
| Lead sponsor | Bhuvaneswari Ramaswamy, Other |
| Collaborators | Genentech, Inc. Industry Case Comprehensive Cancer Center University of Pittsburgh |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab, Bevacizumab, Docetaxel |
| Enrollment | 26 |
| Start date | Jun 14, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Feb 7, 2017 |
| First posted | Jan 30, 2007 |
| Last update posted | Aug 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: